GPP-TSAIII nanocomposite hydrogel-based photothermal ablation facilitates melanoma therapy

BACKGROUND: Photothermal therapy (PTT) is a promising cancer treatment, but its application is limited by low photoconversion efficiency. In this study, we aimed to develop a novel graphene oxide (GO)-based nanocomposite hydrogel to improve the bioavailability of timosaponin AIII (TSAIII) while maximizing PTT efficacy and enhancing the antitumor effect.

METHODS: GO was modified via physical cross-linking with polyvinyl alcohol. The pore structure of the gel was adjusted by repeated freeze-thawing and the addition of polyethylene glycol 2000 to obtain a nanocomposite hydrogel (GPP). The GPP loaded with TSAIII constituted a GPP-TSAIII drug delivery system, and its efficacy was evaluated by in vitro cytotoxicity, apoptosis, migration, and uptake analyses, and in vivo antitumor studies.

RESULTS: The encapsulation rate of GPP-TSAIII was 66.36 ± 3.97%, with slower in vitro release and higher tumor cell uptake (6.4-fold) compared to TSAIII. GPP-TSAIII in combination with PTT showed better bioavailability and antitumor effects in vivo than did TSAIII, with a 1.9-fold higher tumor suppression rate than the TSAIII group.

CONCLUSIONS: GPP is a potential vehicle for delivery of TSAIII-like poor water-soluble anticancer drugs. The innovative PTT co-delivery system may serve as a safe and effective melanoma treatment platform for further anticancer translational purposes.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:20

Enthalten in:

Expert opinion on drug delivery - 20(2023), 9 vom: 19. Juli, Seite 1277-1295

Sprache:

Englisch

Beteiligte Personen:

Huang, Xing [VerfasserIn]
He, Yihao [VerfasserIn]
Zhang, Miao [VerfasserIn]
Lu, Zhenhui [VerfasserIn]
Zhang, Tong [VerfasserIn]
Wang, Bing [VerfasserIn]

Links:

Volltext

Themen:

Antineoplastic Agents
Graphene oxide
Journal Article
Melanoma
Mitochondria
Nanogels
Photothermal therapy
Research Support, Non-U.S. Gov't
Timosaponin AIII
Tumor therapy

Anmerkungen:

Date Completed 02.11.2023

Date Revised 02.11.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1080/17425247.2023.2200997

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM355438577